Skip to main content
About us
Who We Are
Leadership Team
Board of Directors
Scientific Advisors
AI platform technologies
Pipeline
Overview
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Contact us
Site Search
open mobile navigation
Press Releases
close mobile navigation
About us
Who We Are
Leadership Team
Board of Directors
Scientific Advisors
AI platform technologies
Pipeline
Overview
Investors
Overview
Evaxion Shares
Share Data
Share Charts
Historical Lookup
Investment Calculator
Analyst Coverage
Reports & Presentations
Quarterly Reports
Annual Reports
SEC Filings
Financial Calendar
Presentations
Corporate Governance
Governance Documents
Committees
Annual Shareholder Meeting
Resources
Investor FAQs
News & Events
Press Releases
Events
Stay in Touch
Careers
Contact
Contact us
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
11/09/2021
Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
11/09/2021
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
11/05/2021
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
10/26/2021
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital
10/25/2021
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
10/14/2021
Evaxion Biotech Wins Frost & Sullivan 2021 Enabling Technology Leadership Award
Download
PDF format download (opens in new window)
10/12/2021
Evaxion Biotech to Present Work on AI-Immunology Core Technology at Immuno UK 2021
09/21/2021
Evaxion Biotech Appoints Dr. Birgitte Rønø as Chief Scientific Officer
08/12/2021
Evaxion Biotech Announces Q2 2021 Financial Results and Provides Business Update
07/08/2021
Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02
07/07/2021
Evaxion Biotech to Host Conference Call on EVX-01 and EVX-02 Phase 1/2a Data on July 8
06/25/2021
Evaxion Develops Method to Enhance AI Drug Development with Deep Probabilistic Programming
06/03/2021
Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine
05/26/2021
Evaxion Biotech Appoints Lars Holtug to the Board of Directors
05/13/2021
Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update
Download
PDF format download (opens in new window)
05/06/2021
Evaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13
04/20/2021
Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy
04/06/2021
Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update
03/30/2021
Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6
03/16/2021
Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports
02/16/2021
Evaxion Biotech Opens New Office and Laboratories to Support Future Growth
02/10/2021
Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares
Download
PDF format download (opens in new window)
02/04/2021
Evaxion Biotech Announces Pricing of Initial Public Offering
Download
PDF format download (opens in new window)
01/08/2021
Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities
Download
PDF format download (opens in new window)